JP2010520284A - Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト - Google Patents
Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト Download PDFInfo
- Publication number
- JP2010520284A JP2010520284A JP2009552711A JP2009552711A JP2010520284A JP 2010520284 A JP2010520284 A JP 2010520284A JP 2009552711 A JP2009552711 A JP 2009552711A JP 2009552711 A JP2009552711 A JP 2009552711A JP 2010520284 A JP2010520284 A JP 2010520284A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- tlr3
- poly
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008230 Toll-like receptor 3 Human genes 0.000 title claims abstract description 106
- 108010060885 Toll-like receptor 3 Proteins 0.000 title claims abstract description 106
- 239000000556 agonist Substances 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 24
- 229920002477 rna polymer Polymers 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims description 53
- 208000015181 infectious disease Diseases 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 13
- 230000003612 virological effect Effects 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000002689 Toll-like receptor Human genes 0.000 claims description 6
- 108020000411 Toll-like receptor Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 108090000944 RNA Helicases Proteins 0.000 claims description 5
- 102000004409 RNA Helicases Human genes 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 241000713112 Orthobunyavirus Species 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000003308 immunostimulating effect Effects 0.000 abstract description 6
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 93
- 241000713126 Punta Toro virus Species 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 102100026720 Interferon beta Human genes 0.000 description 19
- 108090000467 Interferon-beta Proteins 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 17
- 108010082126 Alanine transaminase Proteins 0.000 description 15
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000009885 systemic effect Effects 0.000 description 13
- 208000019423 liver disease Diseases 0.000 description 11
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 10
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 241001493065 dsRNA viruses Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 229960000329 ribavirin Drugs 0.000 description 7
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 4
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 3
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 2
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 2
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 2
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 241000714198 Caliciviridae Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 208000000705 Rift Valley Fever Diseases 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 102000010982 eIF-2 Kinase Human genes 0.000 description 2
- 108010037623 eIF-2 Kinase Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000011542 interferon-beta production Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 241000114864 ssRNA viruses Species 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241001292006 Arteriviridae Species 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000776207 Bornaviridae Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001534527 Roniviridae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 101150029539 Tlr3 gene Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000010472 type I IFN response Effects 0.000 description 1
- 230000014567 type I interferon production Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90479207P | 2007-03-05 | 2007-03-05 | |
| PCT/US2008/002874 WO2008109083A2 (en) | 2007-03-05 | 2008-03-05 | Restrictive agonist of toll-like receptor 3 (tlr3) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520284A true JP2010520284A (ja) | 2010-06-10 |
| JP2010520284A5 JP2010520284A5 (enExample) | 2011-06-02 |
Family
ID=39738981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552711A Pending JP2010520284A (ja) | 2007-03-05 | 2008-03-05 | Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100183638A1 (enExample) |
| EP (1) | EP2134172A4 (enExample) |
| JP (1) | JP2010520284A (enExample) |
| KR (1) | KR20090130019A (enExample) |
| CN (1) | CN101652062A (enExample) |
| AU (1) | AU2008223446B2 (enExample) |
| BR (1) | BRPI0808637A2 (enExample) |
| CA (1) | CA2680134A1 (enExample) |
| NZ (1) | NZ579433A (enExample) |
| WO (1) | WO2008109083A2 (enExample) |
| ZA (1) | ZA200905954B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532976A (ja) * | 2010-06-25 | 2013-08-22 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006322073A1 (en) | 2005-12-07 | 2007-06-14 | Hemispherx Biopharma, Inc. | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants |
| AU2009215128A1 (en) * | 2008-02-15 | 2009-08-20 | Hemispherx Biopharma, Inc. | Selective agonist of toll-like receptor 3 |
| SI2340307T1 (sl) | 2008-10-23 | 2016-02-29 | Hemispherx Biopharma, Inc. | Dvoverižne ribonukleinske kisline z robustno fizikalno-kemijsko strukturo in zelo specifično biološko aktivnostjo |
| US8722874B2 (en) | 2008-10-23 | 2014-05-13 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| US20100160413A1 (en) | 2008-10-23 | 2010-06-24 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| HUE031756T2 (en) * | 2008-10-31 | 2017-07-28 | Janssen Biotech Inc | TLR3 antagonists |
| WO2011072871A1 (en) * | 2009-12-18 | 2011-06-23 | Bavarian Nordic A/S | Production of ifn-lambda by conventional dendritic cells and uses thereof |
| CN101780279B (zh) * | 2009-12-22 | 2012-07-11 | 中山大学中山眼科中心 | Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用 |
| WO2011130379A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| WO2015127002A1 (en) * | 2014-02-19 | 2015-08-27 | The Johns Hopkins University | Compositions and methods for promoting skin regeneration and hair growth |
| EP3321362A1 (en) | 2016-11-10 | 2018-05-16 | Centre Leon Berard | Tlr3 agonist for use for inducing apoptosis in senescent cancer cells |
| MX2019007583A (es) * | 2016-12-22 | 2019-09-04 | Intervet Int Bv | Vacuna de eimeria con una eficacia mejorada. |
| EP3833383A1 (en) | 2018-08-06 | 2021-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
| WO2020232226A1 (en) | 2019-05-16 | 2020-11-19 | The Johns Hopkins University | Compositions and methods for skin rejuvenation |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01131119A (ja) * | 1987-08-12 | 1989-05-24 | Hem Res Inc | 二本鎖ｒｎａを含んで成る非経口投与剤 |
| US6080726A (en) * | 1985-08-12 | 2000-06-27 | University Of Maryland | Anti-viral and immuno stimulator polynucleotide duplex and use thereof |
| WO2006054177A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer using tlr3 agonists |
| WO2006124676A1 (en) * | 2005-05-17 | 2006-11-23 | The Interthyr Corporation | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5063209A (en) * | 1985-08-26 | 1991-11-05 | Hem Research, Inc. | Modulation of aids virus-related events by double-stranded RNAs |
| US5683986A (en) * | 1987-08-12 | 1997-11-04 | Hemispherx Biopharma Inc. | Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment |
| AU3583797A (en) * | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Enhancement of cancer cell death |
| GB0119346D0 (en) * | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
-
2008
- 2008-03-05 AU AU2008223446A patent/AU2008223446B2/en not_active Ceased
- 2008-03-05 WO PCT/US2008/002874 patent/WO2008109083A2/en not_active Ceased
- 2008-03-05 NZ NZ579433A patent/NZ579433A/en not_active IP Right Cessation
- 2008-03-05 CA CA002680134A patent/CA2680134A1/en not_active Abandoned
- 2008-03-05 CN CN200880007263A patent/CN101652062A/zh active Pending
- 2008-03-05 EP EP08726414A patent/EP2134172A4/en not_active Withdrawn
- 2008-03-05 JP JP2009552711A patent/JP2010520284A/ja active Pending
- 2008-03-05 US US12/530,148 patent/US20100183638A1/en not_active Abandoned
- 2008-03-05 KR KR1020097020751A patent/KR20090130019A/ko not_active Ceased
- 2008-03-05 BR BRPI0808637-0A patent/BRPI0808637A2/pt not_active IP Right Cessation
-
2009
- 2009-08-27 ZA ZA2009/05954A patent/ZA200905954B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080726A (en) * | 1985-08-12 | 2000-06-27 | University Of Maryland | Anti-viral and immuno stimulator polynucleotide duplex and use thereof |
| JPH01131119A (ja) * | 1987-08-12 | 1989-05-24 | Hem Res Inc | 二本鎖ｒｎａを含んで成る非経口投与剤 |
| WO2006054177A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer using tlr3 agonists |
| WO2006124676A1 (en) * | 2005-05-17 | 2006-11-23 | The Interthyr Corporation | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors |
Non-Patent Citations (5)
| Title |
|---|
| JPN7013000238; Ｈｏｗａｒｄ Ｒ． Ｈｕｂｂｅｌｌ， ｅｔ ａｌ．， Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ． Ｉｍｍｕｎｏｔｈｅｒ．， １９９２， ３５， ｐｐ１５１-１５７ * |
| JPN7013000239; Ｃａｔｈｅｒｉｎｅ Ａｍｌｉｅ-ＬｅＦｏｎｄ， ＭＤ， ｅｔ ａｌ．， Ｊ． Ａｌｌｅｒｇｙ Ｃｌｉｎ． Ｉｍｍｕｎｏｌ．， ２００５， １１６（６）， ｐｐ１３３４-１３４２ * |
| JPN7013000240; Ｍ． Ａｄａｍｓ， ｅｔ ａｌ．， Ｖａｃｃｉｎｅ， ２００５， ２３（１７-１８）， ｐｐ２３７４-２３７８ * |
| JPN7013000241; Ｅｌｉｚａｖｅｔａ Ｐａｄａｌｋｏ， ｅｔ ａｌ．， Ａｎｔｉｍｉｃｒｏｂｉａｌ Ａｇｅｎｔｓ ａｎｄ Ｃｈｅｍｏｔｈｅｒａｐｙ， ２００４， ４８（１）， ｐｐ２６７-２７４ * |
| JPN7013000242; "Ｎｅｗ Ｒｅｓｅａｒｃｈ Ｆｒｏｍ Ｈｅｍｉｓｐｈｅｒｘ Ｂｉｏｐｈａｒｍａ Ｌｅｖｅｒａｇｅｓ Ｒｅｃｅｎｔ Ｓｔｕｄｉｅｓ ｔｏ Ｉｄｅｎｔｉｆｙ Ｆａｃｔｏｒｓ ｉｎ Ｂｒｅａｋｄｏｗｎ ｏｆ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532976A (ja) * | 2010-06-25 | 2013-08-22 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0808637A2 (pt) | 2014-08-05 |
| WO2008109083A2 (en) | 2008-09-12 |
| CA2680134A1 (en) | 2008-09-12 |
| WO2008109083A3 (en) | 2008-11-27 |
| ZA200905954B (en) | 2011-10-26 |
| EP2134172A2 (en) | 2009-12-23 |
| NZ579433A (en) | 2012-05-25 |
| US20100183638A1 (en) | 2010-07-22 |
| EP2134172A4 (en) | 2011-06-01 |
| AU2008223446B2 (en) | 2012-02-02 |
| CN101652062A (zh) | 2010-02-17 |
| KR20090130019A (ko) | 2009-12-17 |
| AU2008223446A1 (en) | 2008-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520284A (ja) | Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト | |
| Koyama et al. | Innate immune response to viral infection | |
| JP2023011840A (ja) | 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途 | |
| JP6977206B2 (ja) | 自然免疫を活性化する粘膜ワクチン用アジュバント | |
| US20190292545A1 (en) | 5'-triphosphate oligoribonucleotides | |
| WO2005083076A1 (ja) | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド | |
| CN117050986B (zh) | 具有免疫刺激活性的CpG寡聚核苷酸及其用途 | |
| US20100310600A1 (en) | Selective agonist of toll-like receptor 3 | |
| JP3208138B2 (ja) | ウイルス性肝炎の診断及び治療 | |
| Yang et al. | Association of the expression of Th cytokines with peripheral CD4 and CD8 lymphocyte subsets after vaccination with FMD vaccine in Holstein young sires | |
| CA2632516C (en) | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
| JP2007099747A (ja) | トリインフルエンザ感染の治療 | |
| WO2015167616A1 (en) | Guanosine as an immunepotentiator mediated through toll receptors | |
| Logue et al. | Treatment with cationic liposome–DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge | |
| EP2683369B1 (en) | Multiantivirus compound, composition and method for treatment of virus diseases | |
| US7550150B2 (en) | Methods of treating or preventing a disease, disorder or condition associated with a viral infection | |
| HK1136158A (en) | Restrictive agonist of toll-like receptor 3 (tlr3) | |
| Mitchell | TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly (I: C12U), but not Poly (I: C): differential recognition of synthetic dsRNA molecules | |
| AU2013206335B2 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130424 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130502 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130926 |